Therapeutic drug monitoring in HIV infection: current status and future directions. - Wikidata - wikimedia - TriplyDB

Therapeutic drug monitoring in HIV infection: current status and future directions.

Therapeutic drug monitoring in HIV infection: current status and future directions.

http://www.wikidata.org/entity/Q34660139

about

Therapeutic drug monitoring of antiretrovirals for people with HIV Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania Lamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in China Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.Pharmacokinetics of lamivudine & stavudine in generic fixed-dose combinations in HIV-1 infected adults in India Practical and conceptual challenges in measuring antiretroviral adherence.Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial The role of clinical pharmacology in optimizing antiretroviral therapy.Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.Pharmacologic perspectives for once-daily antiretroviral therapy.Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review.Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS Drug interactions between proton pump inhibitors and antiretroviral drugs.HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-human primate, Macaca nemestrina.Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults Therapeutic drug monitoring in highly active antiretroviral therapy.Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection.Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients Pharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV.Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice.Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.

P2860

Q24239932-D474325B-07E0-40E6-A841-936F93A9E79A Q28533168-1F333A28-88BA-46B6-8A6F-C61768BD6108 Q28551633-48B6AAEF-33F5-4B04-B1C9-7B2F94BC1A0C Q33559015-046D3145-2114-4F2E-A7A2-2CBFC9FC1C3D Q33785839-25E74DE0-675C-40FE-AC26-958BF53A8CB2 Q33835857-D2969B89-DE93-4CDF-9130-5B62EAC6734D Q33914723-92506291-D08E-41A6-92DD-31678EE10F06 Q33927106-D06BED18-B86E-4C4C-985B-BE6A84F8C927 Q34077060-7E27DE66-6025-4AFA-BE60-8DB2F463BA29 Q34103495-53F995E6-E9F2-4B03-80EB-8456FA28566E Q35130818-D2A18C52-D9D0-4395-B538-DFE832A938DF Q35547290-ACBFBC30-6AAE-4E09-9E7E-DA6C30AE2E54 Q35636071-5D1F30EA-E667-48DE-9298-145028B7A74E Q35827870-67A32F79-E4C3-4480-A54A-15693E5CD2B6 Q35915916-6BEA4955-DB96-4698-B4C3-96E05D8058B5 Q36024483-E0529DA4-DA4A-4D0E-8194-9A820910CA57 Q36238198-8336DA25-783B-4030-96EF-4D73461D9380 Q36277913-1487D458-18DE-426C-9934-7BD5BE7A7F93 Q36336929-44353656-2F26-4F2D-AFA5-8D981D3BB38A Q36376533-6C7475D6-2D44-4D79-A31D-A133E351B2C0 Q36544977-8F61365C-842D-4D10-BC4D-E8FA3C6B6250 Q36683435-EB461A02-973D-4348-B1E1-47217C7425DC Q36708715-37451211-97AD-4672-8366-41CF7F3CA82F Q36788409-0154FFFE-61BF-4DC9-9769-AAC392C41998 Q36877910-AFF27E7A-ADA8-450A-8CE5-74DB6FC74C29 Q37199040-BC0860A4-343C-4C48-B4E5-F34B111D0F01 Q37268002-CE3706DB-E3DC-4426-97DA-DEB746604CBC Q37598597-66091E44-97EE-4E36-A4C0-A0559E8DADFB Q37720765-AA3598EA-ADBC-40B2-94CC-D48262127638 Q38086335-584A206A-BAA4-4BDA-80B7-DF219E0F6581 Q38213320-9863B21E-686A-4BFE-AAD1-2F5B97AA3B49 Q38377051-D399771D-B9F3-42CC-9329-0E2E74D562BE Q41021229-83E012FA-12D2-4F3F-ACD9-656F4F093461 Q41906771-B2F22F54-4121-441E-96AE-F03CDDC74888 Q41910769-615F5862-0A9B-4678-B9BF-E5A99C50BC2A Q42248475-A163C886-D525-4C08-922F-62A04CEDFB43 Q43469365-32B59973-7668-442E-9BF8-85FC054A25B0 Q45255502-A136D347-F8B3-4D07-AD55-05295D001C12 Q45722783-0C7EF61A-FDCC-4C43-B76B-E0408570B747 Q46504597-F4A4E8DF-2317-4352-85B9-65F3C8D59B2D

P2860

Therapeutic drug monitoring in HIV infection: current status and future directions.

http://www.wikidata.org/entity/Q34660139

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Therapeutic drug monitoring in HIV infection: current status and future directions.

@ast

Therapeutic drug monitoring in HIV infection: current status and future directions.

@en

Therapeutic drug monitoring in HIV infection: current status and future directions.

@nl

type

label

Therapeutic drug monitoring in HIV infection: current status and future directions.

@ast

Therapeutic drug monitoring in HIV infection: current status and future directions.

@en

Therapeutic drug monitoring in HIV infection: current status and future directions.

@nl

prefLabel

Therapeutic drug monitoring in HIV infection: current status and future directions.

@ast

Therapeutic drug monitoring in HIV infection: current status and future directions.

@en

Therapeutic drug monitoring in HIV infection: current status and future directions.

@nl

P1433

Q34660139-4600375A-2ADB-4823-A3D6-3936B33002D6

P1476

Q34660139-6C8D66D2-056E-468D-BBC1-F1DFF0E5BB06

P2093

Q34660139-1083BCE3-62D7-4BAF-9743-43D00505EDFA

Q34660139-13C56772-56D9-428C-B185-ED6BC4134ACE

Q34660139-4EE6E1CE-6B53-4085-83F7-0743A37D501D

Q34660139-6F9C2298-0D35-4D5C-B78C-40EB3809EAE8

Q34660139-72973795-C903-4EBE-842A-575EBD38C54E

Q34660139-96BB031C-03C6-49C6-BB25-BCF36237F5D3

Q34660139-B30B9976-9413-4078-AB40-CE03D2A05648

Q34660139-C705D659-E461-4E1A-8B9A-511BA00895BB

Q34660139-C8CC9B7E-BED4-4824-9C37-26FC729E2406

Q34660139-D89E2EEB-97DD-4E01-8A3A-F9097B960966

P304

Q34660139-197FD4C0-99C2-4B2C-92DE-F10E4E331070

P31

Q34660139-584DFA0C-5F24-4966-AD2E-AB6F09D06576

P356

Q34660139-E9719EE5-D553-410F-82A2-EB5BC0385A2F

P407

Q34660139-024F2B83-E11C-4E2F-A19C-8EA7276EB847

P478

Q34660139-849726B4-E801-4FA8-BC41-71EB65350859

P577

Q34660139-8E361BE8-83D6-49CA-956F-8707A5B6B068

P698

Q34660139-50D642D4-1527-4E27-BC49-D040751E9F9B

P921

Q34660139-C003CA9D-819A-4417-9E92-02514D2F533F

P356

00002030-200203001-00002

P1433

P1476

Therapeutic drug monitoring in HIV infection: current status and future directions.

@en

P2093

Andrew Luber

http://www.w3.org/2001/XMLSchema#string

Carlo-Federico Perno

http://www.w3.org/2001/XMLSchema#string

Concepta Merry

http://www.w3.org/2001/XMLSchema#string

Courtney Fletcher

http://www.w3.org/2001/XMLSchema#string

David Back

http://www.w3.org/2001/XMLSchema#string

Giorgio Gatti

http://www.w3.org/2001/XMLSchema#string

Michael Kurowski

http://www.w3.org/2001/XMLSchema#string

Richard Haubrich

http://www.w3.org/2001/XMLSchema#string

Richard Hoetelmans

http://www.w3.org/2001/XMLSchema#string

Rodolphe Garaffo

http://www.w3.org/2001/XMLSchema#string

P304

S5-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00002030-200203001-00002

http://www.w3.org/2001/XMLSchema#string

P407

P478

16 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12035820

http://www.w3.org/2001/XMLSchema#string

P921